Altimmune Stock Price, News & Analysis

Altimmune announced interim results from its Phase 1 trial of ALT-801, a dual GLP-1/glucagon receptor agonist, showing a significant 5.4% weight loss at 6 weeks with a 1.8 mg dose, exceeding the 2% target. The treatment was well-tolerated with low nausea rates. Further developments include plans to file an additional IND for an obesity program in 2021 and an anticipated 12-week data readout in Q3 2021. The trial aims to explore ALT-801's effects on liver fat and metabolic conditions, enhancing its therapeutic potential in tackling obesity and NASH.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, will participate in the 2021 Jefferies Virtual Healthcare Conference from June 1 to 4, 2021. The management team, including Vipin Garg, Scot Roberts, and Scott Harris, will present on June 2, 2021 at 11:30 am ET. Attendees can access the presentation through a webcast link on the Altimmune website. Altimmune focuses on developing intranasal vaccines and therapies for various diseases, including its COVID-19 vaccine, AdCOVID™.

Altimmune reported promising preclinical results for its AdCOVID vaccine against the South African variant B.1.351. The neutralizing titers against this variant were only 4.4-fold lower than those against the original SARS-CoV-2 strain after a single intranasal dose. A booster dose further narrowed this gap to 1.8-fold. The study also highlighted strong mucosal immunity, suggesting that AdCOVID could effectively combat variants while simplifying vaccination strategies. The company aims to report Phase 1 trial data in June 2021, with a focus on its potential to provide broad immune responses.

Altimmune, a clinical-stage biopharmaceutical company, reported financial results for Q1 2021, highlighting approximately $227 million in cash and short-term investments. Upcoming data readouts from the Phase 1 clinical trials of AdCOVID and ALT-801 are expected in June. The company anticipates a comprehensive Phase 2 trial for AdCOVID if results are favorable. ALT-801 also shows promise for treating non-alcoholic steatohepatitis (NASH) and obesity. However, Q1 revenue fell 64% year over year to $0.8 million, while net loss increased to $14.9 million, reflecting higher expenses.

Altimmune, Inc. (Nasdaq: ALT) will announce its first quarter 2021 financial results on May 17, 2021. The company, focused on developing intranasal vaccines and therapies, will hold a conference call at 8:30 am ET to discuss these results and provide updates on its business. The call can be accessed via a domestic dial-in at 877-423-9813 or internationally at 201-689-8573, using the conference ID 13719206. Investors can also join the webcast to get insights into Altimmune's pipeline, including its promising COVID-19 vaccine candidate, AdCOVID™.

Altimmune has reported promising preclinical results for its COVID-19 vaccine candidate, AdCOVID. A single intranasal dose of AdCOVID demonstrated sterilizing immunity in the lungs of vaccinated mice, showing no detectable levels of infectious virus after exposure to SARS-CoV-2. This study signifies a potential breakthrough in preventing viral transmission, crucial amid increasing vaccine hesitancy. The ongoing Phase 1 trial is set to deliver topline data in June 2021, assessing safety and immune response, while AdCOVID's features may enhance vaccine acceptance globally.

Altimmune (Nasdaq: ALT) has announced that its management team will present at two significant scientific conferences in May 2021. Scot Roberts, Ph.D. and Dr. Sarah K. Browne will discuss the AdCOVID™ intranasal COVID-19 vaccine at the World Vaccine Congress from May 4-7, 2021. Additionally, Dr. Scott Harris will present on HepTcell™, a therapy for chronic hepatitis B, at the Chronic Hepatitis B Drug Development Virtual Summit on May 5-6, 2021. Presentation materials will be available on the Altimmune website.

AVG Group Sarl has made a strategic investment of approximately NOK 80,000,000 in Alternus Energy Group PLC, bolstering its position in the Nordic renewable energy sector. Alternus aims to become one of the largest pan-European solar operators by the end of the decade. This partnership will enable AVG to provide further financing and expertise in solar technology, enhancing Alternus's operations in Norway. Currently, Alternus has a portfolio of 39 solar parks with over 140 MWp capacity and plans to acquire an additional 1.2 GW of projects by 2023, aiming for over 2 GW by 2025.

Altimmune, Inc. (Nasdaq: ALT) announced results from its Phase 1b trial evaluating the safety and immunogenicity of its intranasal anthrax vaccine candidate, NasoShield. The trial, supported by BARDA, involved 42 healthy volunteers. Key findings indicated significant serum binding antibody responses to the protective antigen compared to placebo. However, responses blocking anthrax toxin were lower than in previous studies with BioThrax. Importantly, 80% of subjects exhibited mucosal IgA responses. The vaccine was well-tolerated. Next steps will involve discussions with BARDA regarding further development funding.